公开(公告)号：EP2712862A1

公开(公告)日：2014-04-02

申请号：EP12186684.2

申请日：2012-09-28

申请人： Splicos ,  Centre National de la Recherche Scientifique ,  Institut Curie ,  Université Montpellier II

发明人： Roux, Pierre ,  Mahuteau, Florence ,  Najman, Romain ,  Gadea, Gilles ,  Tazi, Jamal ,  Scherrer, Didier ,  Brock, Carsten ,  Cahuzac, Nathalie, M.

IPC分类号： C07D213/75 ,  C07D239/42 ,  C07D401/12 ,  A61K31/44 ,  A61P35/00

CPC分类号： C07D401/14 ,  C07D213/75 ,  C07D239/42 ,  C07D401/12

摘要： The present invention relates to a compound of formula (I):

wherein
A and A' independently represent a phenylene group or a pyridylene group; R 2 is a hydrogen atom or a (C 1 -C 4 )alkyl group; R 3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R 4 is a carbonyl group or a sulfonyl group; and R 5 is a - NH-(CH 2 ) a -NR 6 R 7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R 6 and R 7 representing independently a (C 1 -C 4 )alkyl group, or R 6 and R 7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.
The invention further relates to pharmaceutical compositions containing a compound of formula (I) or any one of its pharmaceutically acceptable salt and a preparation process for obtaining the same. Said compounds (I) are useful for treating cancer.

摘要翻译： 本发明涉及式（I）化合物：其中A和A'独立地表示亚苯基或亚吡啶基; R 2是氢原子或（C 1 -C 4）烷基; R 3为2-吡啶基，3-吡啶基，4-吡啶基，2-嘧啶基，4-嘧啶基或5-嘧啶基; R 4是羰基或磺酰基; 和R 5是-NH - （CH 2）a -NR 6 R 7基或4-甲基哌嗪基，其中1至4的整数，R 6和R 7独立地表示（C 1 -C 4） ）烷基，或R 6和R 7与它们所连接的氮原子一起形成选自4-甲基哌嗪基，吗啉代基，吡咯烷基和哌啶子基的杂环基; 或其药学上可接受的盐中的任何一种。 本发明还涉及含有式（I）化合物或其药学上可接受的盐中的任何一种的药物组合物及其制备方法。 所述化合物（I）可用于治疗癌症。